About the Company
We do not have any company description for Lexeo Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Lexeo Therapeutics, Inc.
Lexeo Therapeutics’ Friedreich Ataxia Gene Therapy Receives FDA Breakthrough Therapy Designation
Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July ...
Analysts Conflicted on These Healthcare Names: Lexeo Therapeutics, Inc ...
Lexeo Therapeutics, Inc. (LXEO) In a report issued on January 16, Luca Issi from RBC Capital maintained a Buy rating on Lexeo Therapeutics, Inc., with a price target of $22.00.
Lexeo Therapeutics Appoints New Chief Financial Officer
Lexeo Therapeutics, Inc. ( ($LXEO) ) has provided an announcement. On August 14, 2025, Lexeo Therapeutics announced the appointment of Louis ...
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically ...
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
Earnings Estimate Revisions for Lexeo Therapeutics, Inc. This company is expected to earn -$2.56 per share for the fiscal year ending December 2024, which represents a year-over-year change of 79.4%.
Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital
Lexeo Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $21.67, implying a 723.95% upside from current levels.
Lexeo Therapeutics Announces License Agreement to Accelerate ...
NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced an in-license agreement with Cornell University to ...
Lexeo Therapeutics Inc News (LXEO) - Investing.com
• Nov 03, 2023 Lexeo Therapeutics (LXEO) Opens At $9.50, IPO Priced at $11 Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing ByInvesting.com • Mar 13, 2024 ...
LXEO | Lexeo Therapeutics Inc. Profile | MarketWatch
Lexeo Therapeutics Inc. 345 Park Avenue South 6th floor New York, New York 10010 Phone1 212 547-9879 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2025 RevenueN/A Net ...
Lexeo Therapeutics, Inc. (LXEO) Receives a Buy from RBC Capital
Lexeo Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $20.80. See today’s best-performing stocks on TipRanks >> ...
Similar Companies
Loading the latest forecasts...